Notice of Preliminary Results

RNS Number : 1566T

Angle PLC

02 July 2018

 

For immediate release

2 July 2018

ANGLE plc ("the Company")

Notification of Preliminary Results and Webcast

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 30 April 2018 on Wednesday 25 July 2018. 

A meeting for analysts will be held at 10:30am on 25 July 2018 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD.

A live webcast of the analyst meeting may be accessed via ANGLE's Investor Centre page, https://angleplc.com/investor-relations/corporate-presentations/. Please log on to the webcast approximately 5 minutes before 10:30am on the day of the results.

A recording of the webcast will be made available on ANGLE's website following the results meeting.

For further information ANGLE:

ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker) Corporate Finance - Adrian Hargrave, Simon Hicks, Max Bullen-Smith Corporate Broking - Alice Lane, Nikita Jain	[phone]
WG Partners (Joint Broker) Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee	[phone]
FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert Evan Smith, Anne Troy (US)	[phone] [phone]

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

Notes for editors

About ANGLE plc     www.angleplc.com 

ANGLE is a world leading liquid biopsy company with sample to answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix^TM system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States. 

ANGLE's analysis technology for proteins and nucleic acids of all types is called Ziplex^® and is based on a patented flow through array technology.  It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types.  A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction.  These technologies can be combined to provide fully automated, sample to answer results in both centralised laboratory and point of use cartridge formats.  It is ideal for measuring gene expression and other markers directly from Parsortix harvests.

ANGLE has established formal collaborations with world-class cancer centres.  These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies.  Details are available here http://www.angleplc.com/the-company/collaborators/

 

END

 

 

NORPGURAQUPRGRB